Computational Modeling of Drugs Against Alzheimer’s Disease

Häftad, Engelska, 2023

3 079 kr

Beställningsvara. Skickas inom 10-15 vardagar

Fri frakt för medlemmar vid köp för minst 249 kr.

This second edition volume expands on the previous edition with updated descriptions on different computational methods encompassing ligand-based, structure-based, and combined approaches with their recent applications in anti-Alzheimer drug design.

Produktinformation

Utgivningsdatum2023-06-30
Mått178 x 254 x 28 mm
Vikt953 g
FormatHäftad
SpråkEngelska
SerieNeuromethods
Antal sidor493
Upplaga2
FörlagSpringer-Verlag New York Inc.
ISBN9781071633137

Tillhör följande kategorier

Biovetenskap inom Naturvetenskap och teknik

Recent Progress in the Treatment Strategies of Alzheimer’s Disease.- Understanding the Mechanisms of Amyloid Beta (Aβ) Aggregation by Computational Modeling.- Recent Advances in Computational Modeling of BACE1 Inhibitors as Anti-Alzheimer Agents.- Modeling of BACE-1 Inhibitors as Anti-Alzheimer’s Agents.- Computational Modeling of Kinase Inhibitors as Anti-Alzheimer Agents.- Computer-Assisted Drug Design: A Toolbox for Novel Tau Kinase Inhibitors and Its Implications in Alzheimer’s Disease.- Computational Modeling Approaches in Search of Anti-Alzheimer Agents: Case Studies of Phosphodiesterase Inhibitors.- Recent Advances in Computational Modeling of Multi-Targeting Inhibitors as Anti-Alzheimer Agents.- Computational Modeling of PET and SPECT Imaging Agents as Diagnostics for Alzheimer’s Disease.- Computational Modeling of DYRK1A Inhibitors as Potential Anti-Alzheimer Agents.- Computational Modeling of MAO Inhibitors as Anti-Alzheimer Agents.- Computational Modeling of Phosphodiesterase Inhibitors as Anti-Alzheimer Agents.- Computational Methods for the Design and Development of Glutaminyl Cyclase Inhibitors in Alzheimer’s Disease.- Basic Information Science Methods for Insight into Neurodegenerative Pathogenesis.- Network Pharmacology for Drug Repositioning in Anti-Alzheimer's Drug Development.- Web Services for the Prediction of ADMET Parameters Relevant to the Design of Neuroprotective Drugs.